Diabetic Nephropathy-Pipeline Review, H2 2015

Diabetic Nephropathy-Pipeline Review, H2 2015


  • Products Id :- GMDHC6960IDB
  • |
  • Pages: 272
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Diabetic Nephropathy-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Diabetic Nephropathy-Pipeline Review, H2 2015', provides an overview of the Diabetic Nephropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Diabetic Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Diabetic Nephropathy Overview 10

Therapeutics Development 11

Pipeline Products for Diabetic Nephropathy-Overview 11

Pipeline Products for Diabetic Nephropathy-Comparative Analysis 12

Diabetic Nephropathy-Therapeutics under Development by Companies 13

Diabetic Nephropathy-Therapeutics under Investigation by Universities/Institutes 18

Diabetic Nephropathy-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Diabetic Nephropathy-Products under Development by Companies 23

Diabetic Nephropathy-Products under Investigation by Universities/Institutes 28

Diabetic Nephropathy-Companies Involved in Therapeutics Development 29

AbbVie Inc. 29

Aerpio Therapeutics, Inc. 30

Antisense Therapeutics Limited 31

Astellas Pharma Inc. 32

AstraZeneca Plc 33

Bayer AG 34

BiOrion Technologies B.V. 35

Cellmid Limited 36

ChemoCentryx, Inc. 37

Concert Pharmaceuticals, Inc. 38

CSL Limited 39

CTI BioPharma Corp. 40

Daiichi Sankyo Company, Limited 41

Dimerix Bioscience Pty Ltd 42

Dong Wha Pharma Co., Ltd. 43

Dynamis Therapeutics, Inc. 44

Eli Lilly and Company 45

F. Hoffmann-La Roche Ltd. 46

Galectin Therapeutics, Inc. 47

GenKyoTex S.A. 48

Gilead Sciences, Inc. 49

GlaxoSmithKline Plc 50

Glucox Biotech AB 51

GNI Group Ltd. 52

Islet Sciences, Inc. 53

Jazz Pharmaceuticals Plc 54

Jenrin Discovery, Inc. 55

Johnson & Johnson 56

Mallinckrodt Plc 57

Mesoblast Limited 58

Mitsubishi Tanabe Pharma Corporation 59

MorphoSys AG 60

NephroGenex, Inc. 61

Noxxon Pharma AG 62

Omeros Corporation 63

OncoImmune, Inc. 64

Otsuka Holdings Co., Ltd. 65

Pfizer Inc. 66

PhytoHealth Corporation 67

ProMetic Life Sciences Inc. 68

Serodus ASA 69

Shire Plc 70

Takeda Pharmaceutical Company Limited 71

Tobira Therapeutics, Inc. 72

Torrent Pharmaceuticals Limited 73

Vascular Pharmaceuticals, Inc. 74

Vicore Pharma AB 75

XOMA Corporation 76

Diabetic Nephropathy-Therapeutics Assessment 77

Assessment by Monotherapy Products 77

Assessment by Target 78

Assessment by Mechanism of Action 82

Assessment by Route of Administration 85

Assessment by Molecule Type 87

Drug Profiles 89

11-RVIVIT-Drug Profile 89

A-717-Drug Profile 90

Antibodies to Inhibit Heparanase for Cancer-Drug Profile 91

APX-115-Drug Profile 92

ASP-8232-Drug Profile 93

ATL-1103-Drug Profile 94

atrasentan hydrochloride-Drug Profile 96

baricitinib-Drug Profile 97

Biologic for Diabetic Nephropathy-Drug Profile 100

BOT-191-Drug Profile 101

C-21-Drug Profile 102

canagliflozin-Drug Profile 104

CCX-140-Drug Profile 106

cenicriviroc mesylate-Drug Profile 108

corticotropin-Drug Profile 110

CS-3150-Drug Profile 112

CSL-346-Drug Profile 114

CTP-499-Drug Profile 115

Cyndacel-M-Drug Profile 117

DMX-250-Drug Profile 119

Drug for Diabetic Nephropathy-Drug Profile 120

Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders-Drug Profile 121

DT-23552-Drug Profile 122

DW-1029M-Drug Profile 123

DYN-12-Drug Profile 124

emapticap pegol-Drug Profile 126

finerenone-Drug Profile 128

gevokizumab-Drug Profile 129

GKT-136901-Drug Profile 133

GKT-831-Drug Profile 135

GRMD-02-Drug Profile 137

GW-610742-Drug Profile 140

JD-5037-Drug Profile 141

JNJ-39933673-Drug Profile 142

KBP-5074-Drug Profile 143

lisofylline-Drug Profile 144

MLN-1202-Drug Profile 146

Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications-Drug Profile 148

Monoclonal Antibody to Inhibit HPTPbeta for Diabetic Nephropathy-Drug Profile 150

Monoclonal Antibody to Inhibit Midkine for Cancer and Inflammatory Disorders-Drug Profile 151

MOR-107-Drug Profile 153

MPC-300IV-Drug Profile 154

MT-3995-Drug Profile 156

Nephrilin-Drug Profile 157

Oligotide-Drug Profile 158

oxypurinol-Drug Profile 160

PBI-4050-Drug Profile 161

PBI-4547-Drug Profile 163

PF-00489791-Drug Profile 164

PHN-033-Drug Profile 165

pirfenidone-Drug Profile 166

pirfenidone-Drug Profile 169

probucol-Drug Profile 170

Pyridoxamine Dihydrochloride-Drug Profile 171

selonsertib-Drug Profile 174

SER-150-Drug Profile 175

SHP-627-Drug Profile 177

Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy-Drug Profile 178

Small Molecules for Diabetic Nephropathy-Drug Profile 179

Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders-Drug Profile 180

Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy-Drug Profile 182

SP-20202-Drug Profile 183

TAK-272-Drug Profile 184

TAK-648-Drug Profile 185

TBE-31-Drug Profile 186

TD-0714-Drug Profile 187

TRC-120038-Drug Profile 188

VPI-2690B-Drug Profile 189

VS-105-Drug Profile 191

XRX-108-Drug Profile 192

XRX-221-Drug Profile 193

Diabetic Nephropathy-Recent Pipeline Updates 194

Diabetic Nephropathy-Dormant Projects 254

Diabetic Nephropathy-Discontinued Products 256

Diabetic Nephropathy-Product Development Milestones 257

Featured News & Press Releases 257

Appendix 266

Methodology 266

Coverage 266

Secondary Research 266

Primary Research 266

Expert Panel Validation 266

Contact Us 266

Disclaimer 267

List of Tables

Number of Products under Development for Diabetic Nephropathy, H2 2015 16

Number of Products under Development for Diabetic Nephropathy-Comparative Analysis, H2 2015 17

Number of Products under Development by Companies, H2 2015 19

Number of Products under Development by Companies, H2 2015 (Contd..1) 20

Number of Products under Development by Companies, H2 2015 (Contd..2) 21

Number of Products under Development by Companies, H2 2015 (Contd..3) 22

Number of Products under Investigation by Universities/Institutes, H2 2015 23

Comparative Analysis by Late Stage Development, H2 2015 24

Comparative Analysis by Clinical Stage Development, H2 2015 25

Comparative Analysis by Early Stage Development, H2 2015 26

Comparative Analysis by Unknown Stage Development, H2 2015 27

Products under Development by Companies, H2 2015 28

Products under Development by Companies, H2 2015 (Contd..1) 29

Products under Development by Companies, H2 2015 (Contd..2) 30

Products under Development by Companies, H2 2015 (Contd..3) 31

Products under Development by Companies, H2 2015 (Contd..4) 32

Products under Investigation by Universities/Institutes, H2 2015 33

Diabetic Nephropathy-Pipeline by AbbVie Inc., H2 2015 34

Diabetic Nephropathy-Pipeline by Aerpio Therapeutics, Inc., H2 2015 35

Diabetic Nephropathy-Pipeline by Antisense Therapeutics Limited, H2 2015 36

Diabetic Nephropathy-Pipeline by Astellas Pharma Inc., H2 2015 37

Diabetic Nephropathy-Pipeline by AstraZeneca Plc, H2 2015 38

Diabetic Nephropathy-Pipeline by Bayer AG, H2 2015 39

Diabetic Nephropathy-Pipeline by BiOrion Technologies B.V., H2 2015 40

Diabetic Nephropathy-Pipeline by Cellmid Limited, H2 2015 41

Diabetic Nephropathy-Pipeline by ChemoCentryx, Inc., H2 2015 42

Diabetic Nephropathy-Pipeline by Concert Pharmaceuticals, Inc., H2 2015 43

Diabetic Nephropathy-Pipeline by CSL Limited, H2 2015 44

Diabetic Nephropathy-Pipeline by CTI BioPharma Corp., H2 2015 45

Diabetic Nephropathy-Pipeline by Daiichi Sankyo Company, Limited, H2 2015 46

Diabetic Nephropathy-Pipeline by Dimerix Bioscience Pty Ltd, H2 2015 47

Diabetic Nephropathy-Pipeline by Dong Wha Pharma Co., Ltd., H2 2015 48

Diabetic Nephropathy-Pipeline by Dynamis Therapeutics, Inc., H2 2015 49

Diabetic Nephropathy-Pipeline by Eli Lilly and Company, H2 2015 50

Diabetic Nephropathy-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 51

Diabetic Nephropathy-Pipeline by Galectin Therapeutics, Inc., H2 2015 52

Diabetic Nephropathy-Pipeline by GenKyoTex S.A., H2 2015 53

Diabetic Nephropathy-Pipeline by Gilead Sciences, Inc., H2 2015 54

Diabetic Nephropathy-Pipeline by GlaxoSmithKline Plc, H2 2015 55

Diabetic Nephropathy-Pipeline by Glucox Biotech AB, H2 2015 56

Diabetic Nephropathy-Pipeline by GNI Group Ltd., H2 2015 57

Diabetic Nephropathy-Pipeline by Islet Sciences, Inc., H2 2015 58

Diabetic Nephropathy-Pipeline by Jazz Pharmaceuticals Plc, H2 2015 59

Diabetic Nephropathy-Pipeline by Jenrin Discovery, Inc., H2 2015 60

Diabetic Nephropathy-Pipeline by Johnson & Johnson, H2 2015 61

Diabetic Nephropathy-Pipeline by Mallinckrodt Plc, H2 2015 62

Diabetic Nephropathy-Pipeline by Mesoblast Limited, H2 2015 63

Diabetic Nephropathy-Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 64

Diabetic Nephropathy-Pipeline by MorphoSys AG, H2 2015 65

Diabetic Nephropathy-Pipeline by NephroGenex, Inc., H2 2015 66

Diabetic Nephropathy-Pipeline by Noxxon Pharma AG, H2 2015 67

Diabetic Nephropathy-Pipeline by Omeros Corporation, H2 2015 68

Diabetic Nephropathy-Pipeline by OncoImmune, Inc., H2 2015 69

Diabetic Nephropathy-Pipeline by Otsuka Holdings Co., Ltd., H2 2015 70

Diabetic Nephropathy-Pipeline by Pfizer Inc., H2 2015 71

Diabetic Nephropathy-Pipeline by PhytoHealth Corporation, H2 2015 72

Diabetic Nephropathy-Pipeline by ProMetic Life Sciences Inc., H2 2015 73

Diabetic Nephropathy-Pipeline by Serodus ASA, H2 2015 74

Diabetic Nephropathy-Pipeline by Shire Plc, H2 2015 75

Diabetic Nephropathy-Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 76

Diabetic Nephropathy-Pipeline by Tobira Therapeutics, Inc., H2 2015 77

Diabetic Nephropathy-Pipeline by Torrent Pharmaceuticals Limited, H2 2015 78

Diabetic Nephropathy-Pipeline by Vascular Pharmaceuticals, Inc., H2 2015 79

Diabetic Nephropathy-Pipeline by Vicore Pharma AB, H2 2015 80

Diabetic Nephropathy-Pipeline by XOMA Corporation, H2 2015 81

Assessment by Monotherapy Products, H2 2015 82

Number of Products by Stage and Target, H2 2015 84

Number of Products by Stage and Mechanism of Action, H2 2015 88

Number of Products by Stage and Route of Administration, H2 2015 91

Number of Products by Stage and Molecule Type, H2 2015 93

Diabetic Nephropathy Therapeutics-Recent Pipeline Updates, H2 2015 199

Diabetic Nephropathy-Dormant Projects, H2 2015 259

Diabetic Nephropathy-Dormant Projects (Contd..1), H2 2015 260

Diabetic Nephropathy-Discontinued Products, H2 2015 261

List of Figures

Number of Products under Development for Diabetic Nephropathy, H2 2015 16

Number of Products under Development for Diabetic Nephropathy-Comparative Analysis, H2 2015 17

Number of Products under Development by Companies, H2 2015 18

Number of Products under Investigation by Universities/Institutes, H2 2015 23

Comparative Analysis by Clinical Stage Development, H2 2015 25

Comparative Analysis by Early Stage Products, H2 2015 26

Assessment by Monotherapy Products, H2 2015 82

Number of Products by Top 10 Targets, H2 2015 83

Number of Products by Stage and Top 10 Targets, H2 2015 83

Number of Products by Top 10 Mechanism of Actions, H2 2015 87

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 87

Number of Products by Top 10 Routes of Administration, H2 2015 90

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 90

Number of Products by Top 10 Molecule Types, H2 2015 92

Number of Products by Stage and Top 10 Molecule Types, H2 2015 92

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Aerpio Therapeutics, Inc.

Antisense Therapeutics Limited

Astellas Pharma Inc.

AstraZeneca Plc

Bayer AG

BiOrion Technologies B.V.

Cellmid Limited

ChemoCentryx, Inc.

Concert Pharmaceuticals, Inc.

CSL Limited

CTI BioPharma Corp.

Daiichi Sankyo Company, Limited

Dimerix Bioscience Pty Ltd

Dong Wha Pharma Co., Ltd.

Dynamis Therapeutics, Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Galectin Therapeutics, Inc.

GenKyoTex S.A.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Glucox Biotech AB

GNI Group Ltd.

Islet Sciences, Inc.

Jazz Pharmaceuticals Plc

Jenrin Discovery, Inc.

Johnson & Johnson

Mallinckrodt Plc

Mesoblast Limited

Mitsubishi Tanabe Pharma Corporation

MorphoSys AG

NephroGenex, Inc.

Noxxon Pharma AG

Omeros Corporation

OncoImmune, Inc.

Otsuka Holdings Co., Ltd.

Pfizer Inc.

PhytoHealth Corporation

ProMetic Life Sciences Inc.

Serodus ASA

Shire Plc

Takeda Pharmaceutical Company Limited

Tobira Therapeutics, Inc.

Torrent Pharmaceuticals Limited

Vascular Pharmaceuticals, Inc.

Vicore Pharma AB

XOMA Corporation

Diabetic Nephropathy Therapeutic Products under Development, Key Players in Diabetic Nephropathy Therapeutics, Diabetic Nephropathy Pipeline Overview, Diabetic Nephropathy Pipeline, Diabetic Nephropathy Pipeline Assessment

select a license

Single User License
USD 2000 INR 130100
Site License
USD 4000 INR 260200
Corporate User License
USD 6000 INR 390300

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com